You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKesson
Medtronic
McKinsey
Express Scripts
Merck

Last Updated: September 29, 2020

DrugPatentWatch Database Preview

Patent: 5,650,389

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,650,389
Title: Methods for the inhibition of complement activation
Abstract:Decorin, a small collagen-binding dermatan sulfate proteoglycan, is widely distributed as a component of extracellular matrices. Using a solid phase binding assay, the inventors demonstrated that decorin bound C1q at physiologic pH and ionic strength. The interaction did not require divalent cations and was time and temperature dependent reaching equilibrium in 4 hours at 37.degree. C. Binding was specific and saturable with an apparent dissociation constant of 7.6.times.10.sup.-9 M. Decorin was shown to bind pepsin-derived fragments containing the collagenous domain of C1q and collagenase-derived fragments containing the globular domain of C1q. Since these fragments share a short sequence of amino acids, this finding suggests that decorin binds to a region of C1q located near the junction of the two domains. Competition studies using purified preparations of the decorin core protein and the glycosaminoglycan chains showed that only the former inhibited binding of decorin to C1q indicating that the interaction is mediated by the decorin core protein. Decorin was shown to inhibit the hemolytic activity of purified C1 as well as C1 in normal human serum. Approximately 50% inhibition was observed at a decorin concentration of 2 .mu.g/ml. Inhibition was not observed if C1 was bound to antigen-complexed antibody. Furthermore, neither the core protein, nor the glycosaminoglycan chain of decorin inhibited C1 indicating that the intact proteoglycan is necessary for functional activity. These studies therefore demonstrate the usefulness of decorin and related proteoglycans in suppression of complement activation of the immune system.
Inventor(s): Krumdieck; Richard (Birmingham, AL), Hook; Magnus A. O. (Houston, TX), Volanakis; John E. (Birmingham, AL)
Assignee: University of Alabama at Birmingham Research Foundation (Birmingham, AL)
Application Number:08/025,357
Patent Claims:see list of patent claims

Details for Patent 5,650,389

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck Sharp & Dohme Corp. ZOSTAVAX zoster vaccine live INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 125123 001 2006-05-25   Start Trial University of Alabama at Birmingham Research Foundation (Birmingham, AL) 2039-09-23 search
Merck Sharp & Dohme Corp. ZOSTAVAX zoster vaccine live INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION 125123 1 2006-05-25   Start Trial University of Alabama at Birmingham Research Foundation (Birmingham, AL) 2039-09-23 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Mallinckrodt
Johnson and Johnson
Dow
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.